Jason McCarthy, Ph.D. Maxim Group
- Jun 19, 2018
By
[social_share_button themes='theme8']
“Atossa has multiple catalysts across several clinical programs coming over the next 12-18 months Both the topical and oral formulations of endoxifen continue to advance and management is executing on its clinical strategy. Catalysts lay ahead as data emerges from ongoing and upcoming studies, which if positive should drive a higher valuation.”
You Might Also Like
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
